Literature DB >> 76222

Relation between plasma oestrone and oestradiol and climacteric symptoms.

J D Hutton, H S Jacobs, M A Murray, V H James.   

Abstract

Plasma levels of oestrone and oestradiol-17beta were determined at 20 or 30 minute intervals for up to 24 hours in 26 postmenopausal or ovariectomised women of similar age, weight, and number of years since menopause or operation. Results in women with both superficial dyspareunia and flushes were compared with those in women with flushes only, and with those in symptomless women. Women with superficial dyspareunia had significantly lower mean concentrations of plasma-oestradiol, but not of oestrone, than symptomless women. Flushes were not related to plasma-oestrogen. The implications of these findings in relation to the optimum dose of oestrogen for treating climacteric symptoms are discussed.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 76222     DOI: 10.1016/s0140-6736(78)90796-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  8 in total

Review 1.  Menopausal symptoms as consequences of dysrhythmia.

Authors:  L Gannon
Journal:  J Behav Med       Date:  1993-08

2.  Estrogen replacement therapy, hot flushes and breast cancer.

Authors:  A Paganini-Hill
Journal:  Can Med Assoc J       Date:  1982-09-01       Impact factor: 8.262

3.  Reduction of menopausal hot flushes by methyldopa. A double blind crossover trial.

Authors:  B I Nesheim; T Saetre
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

4.  Feeling too hot or cold after breast cancer: is it just a nuisance or a potentially important prognostic factor?

Authors:  Kathleen M Kokolus; Chi-Chen Hong; Elizabeth A Repasky
Journal:  Int J Hyperthermia       Date:  2010       Impact factor: 3.914

5.  Dietary pattern influences breast cancer prognosis in women without hot flashes: the women's healthy eating and living trial.

Authors:  Ellen B Gold; John P Pierce; Loki Natarajan; Marcia L Stefanick; Gail A Laughlin; Bette J Caan; Shirley W Flatt; Jennifer A Emond; Nazmus Saquib; Lisa Madlensky; Sheila Kealey; Linda Wasserman; Cynthia A Thomson; Cheryl L Rock; Barbara A Parker; Njeri Karanja; Vicky Jones; Richard A Hajek; Minya Pu; Joanne E Mortimer
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

6.  Tissue-Specific Effects of Loss of Estrogen during Menopause and Aging.

Authors:  Korinna Wend; Peter Wend; Susan A Krum
Journal:  Front Endocrinol (Lausanne)       Date:  2012-02-08       Impact factor: 5.555

Review 7.  Safety of aromatase inhibitors in the adjuvant setting.

Authors:  Edith A Perez
Journal:  Breast Cancer Res Treat       Date:  2007-10-03       Impact factor: 4.872

Review 8.  Steroid endocrinology after the menopause: a review.

Authors:  J D Hutton; H S Jacobs; V H James
Journal:  J R Soc Med       Date:  1979-11       Impact factor: 18.000

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.